Trodelvy expanded to 1L metastatic TNBC Across PD-L1 Status in the EU

Novartis’ Pluvicto receives approval in China for a new indication

Enhertu with Pertuzumab approved in China for 1L HER2-positive metastatic Breast cancer

Hengrui’s Aiweida receives NMPA approval for HER2-positive Colorectal cancer

AbbVie’s Elahere receives Minzdrav approval in Russia for Ovarian, Fallopian tube and Peritoneal cancer

Datroway approved in the EU for first-line metastatic TNBC patients unsuitable for immunotherapy

FDA approves Pluvicto for PSMA+ mHSPC, advancing potential new standard of care across metastatic disease

AstraZeneca receives CDSCO approval for Enhertu followed by THP for adults with HER2-positive stage II...

ImmunityBio receives UAE Marketing Authorization for ANKTIVA in BCG-unresponsive NMIBC (CIS and papillary disease) and...